title: Effect of recombinant human SDF-1a on re-endothelialization after sirolimus-eluting stent implantation in rabbit aorta abdominalis.
abstract: OBJECTIVE
  Although the use of drug-eluting stents (DES) has been shown to limit neointimal hyperplasia in clinical coronary artery disease treatment, currently available DES may adversely affect re-endothelialization (RE) and thus increase fateful stent thrombosis. As stromal cell derived factor 1a (SDF-1a) plays an essential role in the regulation of endothelial progenitor cells (EPCs) mobilization, homing, and differentiation in response to vascular injury, we assumed that SDF-1a may enhance EPCs adhesion and attenuate delayed RE associated with DES.
  
  
  METHODS
  Biologically active recombinant human SDF-1a (rhSDF-1a) was first produced using an Escherichia coli expression system. Twenty-four male rabbits were then underwent sirolimus-eluting stents implantation in aorta abdominalis. After operation, they were randomly divided into two groups and subcutaneously injected daily with 50 μg/kg rhSDF-1a or the same volume of saline for 7 days.
  
  
  RESULTS
  With the application of scanning electron microscopy (SEM) and histological analysis, we found that rhSDF-1a significantly promoted RE on days 7, 14, 28 and inhibited neointimal hyperplasia on day 28 after stent implantation.
  
  
  CONCLUSIONS
  Our results revealed a potential role of rhSDF-1a in facilitating RE and inhibiting neointimal proliferation after DES implantation, leading to a conclusion that this protein may be a potential candidate agent for the treatment of in-stent restenosis and stent thrombosis.
authors: Department of Cardiology, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, PR China.
authors: Lin
authors: L
authors: Zhang
authors: Jinzhou
authors: J
authors: Zhu
authors: Run
authors: R
authors: Du
authors: Zhenbin
authors: Z
authors: Zhu
authors: Jing
authors: J
authors: Zhang
authors: Wei
authors: W
authors: Han
authors: Ruiyan
authors: R
authors: Zhang
mesh_terms: D000818:Animals; D001012:Aorta, Abdominal / Q000378:metabolism*; D054377:Chemokine CXCL12 / Q000494:pharmacology*; D054855:Drug-Eluting Stents; D004730:Endothelium, Vascular / Q000378:metabolism*; D006801:Humans; D006965:Hyperplasia; D008297:Male; D008855:Microscopy, Electron, Scanning; D058426:Neointima / Q000517:prevention & control; D011817:Rabbits; D011994:Recombinant Proteins; D020123:Sirolimus / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D011994:Recombinant Proteins; D020123:Sirolimus